Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways
Molecules · 20.09.2023 · 28 (18) · 6725
DOI: 10.3390/molecules28186725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 20.09.2023. Verfasst von József Király und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Naphthoquinones, Apoptosis, Proto-Oncogene Proteins c-akt, Kidney Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union and the European Regional Development Fund, Thematic Excellence Program.
Abstract (Originalsprache)
(1)
Background
Shikonin, the main ingredient in Chinese herbal medicine, is described as a novel angiogenesis inhibitor, and its anticancer effects have already been studied. Shikonin and its derivatives induce apoptosis and suppress metastasis, which further enhance the effectiveness of chemotherapy. However, their mechanism of function has not been completely elucidated on human renal cancer cells. (2)
Methods
In our study, CAKI-2 and A-498 cells were treated with increasing concentrations (2.5–40 µM) of shikonin, when colony formation ability and cytotoxic activity were tested. The changes in the expression of the main targets of apoptotic pathways were measured by RT-qPCR and Western blot. The intracellular levels of miR-21 and miR-155 were quantified by RT-qPCR. (3)
Results
Shikonin exerted a dose-dependent effect on the proliferation of the cell lines examined. In 5 µM concentration of shikonin in vitro elevated caspase-3 and -7 levels, the proteins of the Ras/MAPK and PI3K/AKT pathways were activated. However, no significant changes were detected in the miR-21 and miR-155 expressions. (4)
Conclusions
Our findings indicated that shikonin causes apoptosis of renal cancer cells by activating the Ras/MAPK and PI3K/AKT pathways. These effects of shikonin on renal cancer cells may bear important potential therapeutic implications for the treatment of renal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
- HUN-RE-DE Pharmamodul Research Group, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, College Station, TX 77845, USA.
ORCID-Profile: Zsolt Fejes, Béla Nagy
Förderung
- European Union and the European Regional Development Fund
- Thematic Excellence Program
Zitieren
APA
Király, J., Szabó, E., Fodor, P., Fejes, Z., Nagy, B., Juhász, É., Vass, A., Choudhury, M., Kónya, G., Halmos, G., & Szabó, Z. (2023). Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways. Molecules, 28(18), 6725. https://doi.org/10.3390/molecules28186725
Vancouver
Király J, Szabó E, Fodor P, Fejes Z, Nagy B, Juhász É, et al. Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways. Molecules. 2023;28(18):6725. doi:10.3390/molecules28186725
BibTeX
@article{Kirly2023,
author = {Király, József and Szabó, Erzsébet and Fodor, Petra and Fejes, Zsolt and Nagy, Béla and Juhász, Éva and Vass, Anna and Choudhury, Mahua and Kónya, Gábor and Halmos, Gábor and Szabó, Zsuzsanna},
title = {Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways},
journal = {Molecules},
year = {2023},
volume = {28},
number = {18},
pages = {6725},
doi = {10.3390/molecules28186725}
}
EUVIMED